lOMoARcPSD|327 44l1O6M9oARcPSD|327 441 69
TEST BANK
, lOMoARcPSD|327 441 69
TABLE OF CONTENT
o Chapter 1: Issues for the Practitioner in Drug Therapy
o Chapter 2: Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
o Chapter 3: Impact of Drug Interactions and Adverse Events on Therapeutics
o Chapter 4: Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactation
o Chapter 5: Pharmacotherapy Principles in Older Adults
o Chapter 6: Principles of Antimicrobial Therapy
o Chapter 7: Pharmacogenomics
o Chapter 8: The Economics of Pharmacotherapeutics
o Chapter 9: Principles of Pharmacology in Pain Management
o Chapter 10: Pain Management in Opioid Use Disorder (OUD) Patients
o Chapter 11: Cannabis and Pain Management
o Chapter 12: Dermatitis
o Chapter 13: Bacterial, Fungal, and Viral Infections of the Skin
o Chapter 14: Psoriasis
o Chapter 15: Acne Vulgaris and Rosacea
o Chapter 16: Ophthalmic Disorders
o Chapter 17: Otitis Media and Otitis Externa
o Chapter 18: Hypertension
o Chapter 19: Hyperlipidemia
o Chapter 20: Chronic Stable Angina and Myocardial Infarction
o Chapter 21: Heart Failure
o Chapter 22: Arrhythmias
o Chapter 23: Respiratory Infections
o Chapter 24: Asthma and Chronic Obstructive Pulmonary Disease
o Chapter 25: Gastric, Functional and Inflammatory Bowel Disorders
o Chapter 26: Gastroesophageal Reflux Disease and Peptic Ulcer Disease
o Chapter 27: Liver Diseases
o Chapter 28: Urinary Tract Infection
o Chapter 29: Prostatic Disorders and Erectile Dysfunction
o Chapter 30: Overactive Bladder
o Chapter 31: Sexually Transmitted Infections
o Chapter 32: Osteoarthritis and Gout
o Chapter 33: Osteoporosis
o Chapter 34: Rheumatoid Arthritis
o Chapter 35: Headaches
o Chapter 36: Seizure Disorders
o Chapter 37: Alzheimer’s Disease
o Chapter 38: Parkinson Disease
o Chapter 39: Major Depressive Disorder and Bipolar Disorders
o Chapter 40: Anxiety Disorders
o Chapter 41: Sleep Disorders
o Chapter 42: Attention Deficit Hyperactivity Disorder
o Chapter 43: Substance Use Disorders
o Chapter 44: Diabetes Mellitus
o Chapter 45: Thyroid and Parathyroid Disorders
o Chapter 46: Allergies and Allergic Reactions o
Chapter 47: Human Immunodeficiency Virus o
Chapter 48: Organ Transplantation
o Chapter 49: Pharmacotherapy for Select Thromboembolic Disorders
o Chapter 50: Anemias
o Chapter 51: Immunizations
o Chapter 52: Smoking Cessation
o Chapter 53: Weight Loss
o Chapter 54: Contraception
, lOMoARcPSD|327 441 69
o Chapter 55: Menopause
o Chapter 56: Vaginitis
Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
, lOMoARcPSD|327 441 69
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to
prescribingbecause:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the
drug. Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
TEST BANK
, lOMoARcPSD|327 441 69
TABLE OF CONTENT
o Chapter 1: Issues for the Practitioner in Drug Therapy
o Chapter 2: Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
o Chapter 3: Impact of Drug Interactions and Adverse Events on Therapeutics
o Chapter 4: Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactation
o Chapter 5: Pharmacotherapy Principles in Older Adults
o Chapter 6: Principles of Antimicrobial Therapy
o Chapter 7: Pharmacogenomics
o Chapter 8: The Economics of Pharmacotherapeutics
o Chapter 9: Principles of Pharmacology in Pain Management
o Chapter 10: Pain Management in Opioid Use Disorder (OUD) Patients
o Chapter 11: Cannabis and Pain Management
o Chapter 12: Dermatitis
o Chapter 13: Bacterial, Fungal, and Viral Infections of the Skin
o Chapter 14: Psoriasis
o Chapter 15: Acne Vulgaris and Rosacea
o Chapter 16: Ophthalmic Disorders
o Chapter 17: Otitis Media and Otitis Externa
o Chapter 18: Hypertension
o Chapter 19: Hyperlipidemia
o Chapter 20: Chronic Stable Angina and Myocardial Infarction
o Chapter 21: Heart Failure
o Chapter 22: Arrhythmias
o Chapter 23: Respiratory Infections
o Chapter 24: Asthma and Chronic Obstructive Pulmonary Disease
o Chapter 25: Gastric, Functional and Inflammatory Bowel Disorders
o Chapter 26: Gastroesophageal Reflux Disease and Peptic Ulcer Disease
o Chapter 27: Liver Diseases
o Chapter 28: Urinary Tract Infection
o Chapter 29: Prostatic Disorders and Erectile Dysfunction
o Chapter 30: Overactive Bladder
o Chapter 31: Sexually Transmitted Infections
o Chapter 32: Osteoarthritis and Gout
o Chapter 33: Osteoporosis
o Chapter 34: Rheumatoid Arthritis
o Chapter 35: Headaches
o Chapter 36: Seizure Disorders
o Chapter 37: Alzheimer’s Disease
o Chapter 38: Parkinson Disease
o Chapter 39: Major Depressive Disorder and Bipolar Disorders
o Chapter 40: Anxiety Disorders
o Chapter 41: Sleep Disorders
o Chapter 42: Attention Deficit Hyperactivity Disorder
o Chapter 43: Substance Use Disorders
o Chapter 44: Diabetes Mellitus
o Chapter 45: Thyroid and Parathyroid Disorders
o Chapter 46: Allergies and Allergic Reactions o
Chapter 47: Human Immunodeficiency Virus o
Chapter 48: Organ Transplantation
o Chapter 49: Pharmacotherapy for Select Thromboembolic Disorders
o Chapter 50: Anemias
o Chapter 51: Immunizations
o Chapter 52: Smoking Cessation
o Chapter 53: Weight Loss
o Chapter 54: Contraception
, lOMoARcPSD|327 441 69
o Chapter 55: Menopause
o Chapter 56: Vaginitis
Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
, lOMoARcPSD|327 441 69
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to
prescribingbecause:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the
drug. Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
